Meningitis, Meningococcal
31
1
3
20
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
13 trials with published results (42%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
9.7%
3 terminated out of 31 trials
87.0%
+0.5% vs benchmark
45%
14 trials in Phase 3/4
65%
13 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (31)
Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
A Study Assessing Colonisation & Immunogenicity After Nasal Inoculation With N. Lactamica and Eradication on Day 4 or 14
A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age
Long-term Sequelae of Childhood Meningitis and Meningococcal Purpura Fulminans
Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds
A Human Controlled Infection Study with Neisseria Lactamica in Malian Adults
Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months
A Sourcing Study to Collect Human Blood Samples From Healthy Adults
Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age
High and Low Resource Interventions to Promote HPV Vaccines
A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine
A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine
Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years
Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018
Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population
RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)